OLIPASS Corporation
OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain. The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD… Read more
OLIPASS Corporation (244460) - Total Liabilities
Latest total liabilities as of December 2024: ₩14.42 Billion KRW
Based on the latest financial reports, OLIPASS Corporation (244460) has total liabilities worth ₩14.42 Billion KRW as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OLIPASS Corporation - Total Liabilities Trend (2016–2024)
This chart illustrates how OLIPASS Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
OLIPASS Corporation Competitors by Total Liabilities
The table below lists competitors of OLIPASS Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
INTERDIGITAL
BE:IDI
|
Germany | €1.00 Billion |
|
RPM Automotive Group Ltd
AU:RPM
|
Australia | AU$57.30 Million |
|
Spentex Industries Limited
NSE:SPENTEX
|
India | ₹579.29 Million |
|
Melkior Resources Inc
PINK:MKRIF
|
USA | $235.55K |
|
MICube Solution Inc
KQ:373170
|
Korea | ₩6.90 Billion |
|
Prima Cakrawala Abadi PT
JK:PCAR
|
Indonesia | Rp22.92 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down OLIPASS Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OLIPASS Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OLIPASS Corporation (2016–2024)
The table below shows the annual total liabilities of OLIPASS Corporation from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩14.42 Billion | +29.75% |
| 2023-12-31 | ₩11.12 Billion | -23.23% |
| 2022-12-31 | ₩14.48 Billion | -5.11% |
| 2021-12-31 | ₩15.26 Billion | -38.56% |
| 2020-12-31 | ₩24.84 Billion | -29.83% |
| 2019-12-31 | ₩35.39 Billion | -48.94% |
| 2018-12-31 | ₩69.32 Billion | -30.64% |
| 2017-12-31 | ₩99.95 Billion | +9.17% |
| 2016-12-31 | ₩91.55 Billion | -- |